Updated US guidelines for high level disinfection
Tristel plc has announced that the American Institute of Ultrasound in Medicine has expanded its US guidelines to include chlorine dioxide for the high-level disinfection of ultrasound probes, a development that positively impacts Tristel's HLD foam product, Tristel ULT™, sold in the US through Parker Laboratories. This inclusion, alongside the recognition of chlorine dioxide foam in the American national standard ANSI/AAMI ST58:2024, is expected to accelerate the adoption of Tristel ULT™ in the US ultrasound market, building on its approval in over 35 countries since 2008.
Select text to share a quote on X · sign in to keep highlights & notes in your TSTL notes
American Institute of Ultrasound in Medicine expands U.S. Guidelines to include chlorine dioxide for high level disinfection of ultrasound probe
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, notes with satisfaction the publication by the American Institute of Ultrasound in Medicine ("AIUM") regarding its expanded guidelines on the handling and reprocessing of ultrasound probes in healthcare environments. For the first time, the AIUM guidelines include chlorine dioxide as an accepted option for high-level disinfection ("HLD").
Chlorine dioxide for ultrasound probe disinfection is branded as Tristel's HLD foam product, Tristel ULT™, in the United States ("US"). Tristel ULT™ is manufactured and distributed by Parker Laboratories under an exclusive partnership agreement with Tristel, and is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes available in the US market.
Matt Sassone, Chief Executive Officer of Tristel plc said: "We are delighted to see AIUM's decision to include chlorine dioxide as an approved method for high-level disinfection for ultrasound instruments. Together with the inclusion last year of chlorine dioxide foam in the American national standard on chemical sterilisation and high-level disinfection (ANSI/AAMI ST58:2024) - which acknowledges this modality as a valid HLD option - this marks a significant milestone for the U.S. market.
"Tristel ULT™ has been approved for use in more than 35 countries since 2008 and this update underscores the importance of our technology in highly sterilised care environments where consistency and compliance are of critical importance.
"With the AIUM guideline update and the enhanced national standard, we believe the conditions are well-aligned for accelerated adoption of Tristel ULT™ in the US ultrasound market - supporting frontline clinicians, infection-prevention teams and hospital administrators alike."
For the full announcement on the revised guidelines from Tristel's partner, Parker Laboratories, please see here.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.